Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Beam Therapeutics Inc. (BEAM)

43.18   -1.1 (-2.48%) 11-28 16:00
Open: 44.19 Pre. Close: 44.28
High: 45.115 Low: 42.54
Volume: 547,256 Market Cap: 3,043(M)

Technical analysis

as of: 2022-11-28 4:38:13 PM
Overall:       
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 54.68     One year: 63.42
Support: Support1: 34.71    Support2: 28.87
Resistance: Resistance1: 46.81    Resistance2: 54.29
Pivot: 44.94
Moving Average: MA(5): 44.79     MA(20): 44.65
MA(100): 53.08     MA(250): 54.61
MACD: MACD(12,26): -0.5     Signal(9): -0.5
Stochastic oscillator: %K(14,3): 49.3     %D(3): 52.5
RSI: RSI(14): 43.5
52-week: High: 88.18  Low: 27.77
Average Vol(K): 3-Month: 900 (K)  10-Days: 585 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ BEAM ] has closed above bottom band by 39.0%. Bollinger Bands are 7.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 45.13 - 45.44 45.44 - 45.69
Low: 41.98 - 42.26 42.26 - 42.5
Close: 42.76 - 43.23 43.23 - 43.61

Company Description

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.

Headline News

Mon, 28 Nov 2022
Where to Find Solar Beam TM in Pokemon Scarlet and Violet - The Nerd Stash

Mon, 28 Nov 2022
Melin Introduces BEAM Collection | Shop-Eat-Surf - Shop-Eat-Surf.com

Mon, 28 Nov 2022
Researchers develop programmable optical device for high-speed beam steering - Phys.org

Mon, 28 Nov 2022
US beam imports down 38.8 percent in September - SteelOrbis

Mon, 28 Nov 2022
Sonos Beam Cyber Monday Deals (2022) Listed by Retail Fuse - AccessWire

Sun, 27 Nov 2022
Tesla Improves Auto High Beam Lights in Update 2022.40 - Not a Tesla App

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 70 (M)
% Held by Insiders 5.78e+007 (%)
% Held by Institutions 2.3 (%)
Shares Short 13,120 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -1.4519e+008
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -171.9
Return on Assets (ttm) -7.9
Return on Equity (ttm) -40.3
Qtrly Rev. Growth 1
Gross Profit (p.s.) 584.69
Sales Per Share 5.53916e+007
EBITDA (p.s.) -1.08608e+008
Qtrly Earnings Growth -3.6
Operating Cash Flow 0 (M)
Levered Free Cash Flow 94 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio -2.4
Price to Book value 0
Price to Sales 0
Price to Cash Flow 6.9

Stock Dividends

Dividend 0
Forward Dividend 1.31e+007
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.